Sign in
4

Changes in Ownership

Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000120

General Counsel sold 9,000 shares at an average $94.89 ($853,986)

  • General Counsel acquired 9,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Quinlan Paul T · General Counsel

Table I: Non-derivative

5 lines
Date Transaction Shares Price Value Owned after D/I
2026-11-20 Exercise or conversion : show line 1 in the form 10b5-1 +9,000 $7.80 $70,200 38,995 D
2026-11-20 Sale : show line 2 in the form 10b5-1 −3,300 $94.05 $310,360 35,695 D
2026-11-20 Sale : show line 3 in the form 10b5-1 −3,000 $94.77 $284,320 32,695 D
2026-11-20 Sale : show line 4 in the form 10b5-1 −2,500 $95.99 $239,986 30,195 D
2026-11-20 Sale : show line 5 in the form 10b5-1 −200 $96.60 $19,320 29,995 D
Open-market sales · 9,000 sh · avg $94.89 · $853,986

Table II: Derivative

1 line
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2026-11-20 Exercise or conversion : show line 6 in the form 10b5-1 Employee Warrant (right to buy) −9,000 $7.80 2034-07-14 9,000 61,996 D
Loading xslF345X06/form4.xml…